Skip to main content
Erschienen in: Cancer Causes & Control 1/2013

01.01.2013 | Original paper

The association between cancer and amyotrophic lateral sclerosis

verfasst von: D. Michal Freedman, Rochelle E. Curtis, Sarah E. Daugherty, James J. Goedert, Ralph W. Kuncl, Margaret A. Tucker

Erschienen in: Cancer Causes & Control | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

Increasing evidence suggests that some neurodegenerative disorders, such as Parkinson’s disease, are inversely related to cancer. Few epidemiologic studies have examined the relationship between cancer and amyotrophic lateral sclerosis (ALS), another major neurodegenerative disease. This study addresses that gap.

Methods

Using data from 16 population-based cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program of the U.S. National Cancer Institute and death certificates, we followed 2.7 million cancer survivors who were diagnosed between 1973 and 2007, and who survived at least 1 year following cancer diagnosis. The standardized mortality ratio (SMR) of observed to expected ALS deaths in cancer survivors was calculated.

Results

A total of 1,216 ALS deaths were reported among 1 year survivors of cancer over 16.6 million person-years of follow-up. ALS mortality was not significantly associated with the incidence of total cancers [SMR = 1.00 (95 % confidence interval (CI), 0.95–1.06)]. There was, however, a significantly elevated risk of ALS death among survivors of melanoma [SMR = 1.49 (95 % (CI), 1.17–1.85)] and of tongue cancer [SMR = 2.57 (95 % CI, 1.41–4.32)], and a significantly reduced ALS death risk among prostate cancer survivors [SMR = 0.86 (95 % CI, 0.76–0.96)].

Conclusions

Cancer at certain sites may be related to risk of ALS death. Possible biologic factors linking ALS to these cancers are discussed. Future studies should attempt to confirm these associations using incident ALS outcomes. Establishing relationships between cancer and neurodegenerative diseases, such as ALS, opens new opportunities for understanding related pathophysiologic and therapeutic possibilities for these diseases.
Literatur
1.
Zurück zum Zitat Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6:e1001257PubMedCrossRef Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6:e1001257PubMedCrossRef
2.
Zurück zum Zitat Tabares-Seisdedos R, Dumont N, Baudot A et al (2011) No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12:604–608PubMedCrossRef Tabares-Seisdedos R, Dumont N, Baudot A et al (2011) No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12:604–608PubMedCrossRef
3.
Zurück zum Zitat Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 11:812–823 Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 11:812–823
4.
Zurück zum Zitat Roe CM, Fitzpatrick AL, Xiong C et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74:106–112PubMedCrossRef Roe CM, Fitzpatrick AL, Xiong C et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74:106–112PubMedCrossRef
5.
Zurück zum Zitat Bajaj A, Driver JA, Schernhammer ES (2010) Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21:697–707PubMedCrossRef Bajaj A, Driver JA, Schernhammer ES (2010) Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21:697–707PubMedCrossRef
6.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205PubMedCrossRef Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205PubMedCrossRef
7.
Zurück zum Zitat Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16:1260–1265PubMedCrossRef Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16:1260–1265PubMedCrossRef
8.
Zurück zum Zitat Driver JA, Beiser A, Au R et al (2012) Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ 344:e1442PubMedCrossRef Driver JA, Beiser A, Au R et al (2012) Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ 344:e1442PubMedCrossRef
9.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17:582–587PubMedCrossRef Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17:582–587PubMedCrossRef
10.
Zurück zum Zitat Freedman DM, Travis LB, Gridley G, Kuncl RW (2005) Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25:176–180PubMedCrossRef Freedman DM, Travis LB, Gridley G, Kuncl RW (2005) Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25:176–180PubMedCrossRef
11.
Zurück zum Zitat Baade PD, Fritschi L, Freedman DM (2007) Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology 28:16–20PubMedCrossRef Baade PD, Fritschi L, Freedman DM (2007) Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology 28:16–20PubMedCrossRef
12.
Zurück zum Zitat Zisfein J, Caroscio JT (1988) No association of amyotrophic lateral sclerosis with cancer. Mt Sinai J Med 55:159–161PubMed Zisfein J, Caroscio JT (1988) No association of amyotrophic lateral sclerosis with cancer. Mt Sinai J Med 55:159–161PubMed
13.
Zurück zum Zitat Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D (1988) Motor neuron disease and malignancies: results of a population-based study. J Neurol 235:374–375PubMedCrossRef Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D (1988) Motor neuron disease and malignancies: results of a population-based study. J Neurol 235:374–375PubMedCrossRef
14.
Zurück zum Zitat Kurtzke JF, Beebe GW (1980) Epidemiology of amyotrophic lateral sclerosis: 1. A case–control comparison based on ALS deaths. Neurology 30:453–462PubMedCrossRef Kurtzke JF, Beebe GW (1980) Epidemiology of amyotrophic lateral sclerosis: 1. A case–control comparison based on ALS deaths. Neurology 30:453–462PubMedCrossRef
15.
Zurück zum Zitat Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194CrossRef Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194CrossRef
16.
17.
Zurück zum Zitat Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955PubMedCrossRef Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955PubMedCrossRef
18.
Zurück zum Zitat Logroscino G, Traynor BJ, Hardiman O et al (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11PubMedCrossRef Logroscino G, Traynor BJ, Hardiman O et al (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11PubMedCrossRef
19.
Zurück zum Zitat Steenland K, MacNeil J, Seals R, Levey A (2010) Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology 35:28–35PubMedCrossRef Steenland K, MacNeil J, Seals R, Levey A (2010) Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology 35:28–35PubMedCrossRef
20.
Zurück zum Zitat Mateen FJ, Carone M, Sorenson EJ (2010) Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004. J Neurol Neurosurg Psychiatry 81:1144–1146PubMedCrossRef Mateen FJ, Carone M, Sorenson EJ (2010) Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004. J Neurol Neurosurg Psychiatry 81:1144–1146PubMedCrossRef
21.
Zurück zum Zitat Chio A, Logroscino G, Hardiman O et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310–323PubMedCrossRef Chio A, Logroscino G, Hardiman O et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310–323PubMedCrossRef
22.
Zurück zum Zitat Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda
23.
Zurück zum Zitat Swan J, Wingo P, Clive R et al (1998) Cancer surveillance in the U.S.: can we have a national system? Cancer 83:1282–1291PubMedCrossRef Swan J, Wingo P, Clive R et al (1998) Cancer surveillance in the U.S.: can we have a national system? Cancer 83:1282–1291PubMedCrossRef
24.
Zurück zum Zitat Leone M, Chandra V, Schoenberg BS (1987) Motor neuron disease in the United States, 1971 and 1973–1978: patterns of mortality and associated conditions at the time of death. Neurology 37:1339–1343PubMedCrossRef Leone M, Chandra V, Schoenberg BS (1987) Motor neuron disease in the United States, 1971 and 1973–1978: patterns of mortality and associated conditions at the time of death. Neurology 37:1339–1343PubMedCrossRef
25.
Zurück zum Zitat Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377PubMedCrossRef Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377PubMedCrossRef
26.
Zurück zum Zitat Baade PD, Herrero Hernandez E, Freedman DM, Smithers BM, Fritschi L (2010) No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson’s disease. Neuroepidemiology 35:303–304PubMedCrossRef Baade PD, Herrero Hernandez E, Freedman DM, Smithers BM, Fritschi L (2010) No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson’s disease. Neuroepidemiology 35:303–304PubMedCrossRef
27.
Zurück zum Zitat Habib AA, Mitsumoto H (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 16:537–558PubMedCrossRef Habib AA, Mitsumoto H (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 16:537–558PubMedCrossRef
28.
Zurück zum Zitat Lee HJ, Wall BA, Wangari-Talbot J et al (2011) Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17:7080–7092PubMedCrossRef Lee HJ, Wall BA, Wangari-Talbot J et al (2011) Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17:7080–7092PubMedCrossRef
29.
Zurück zum Zitat Stepulak A, Luksch H, Gebhardt C et al (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435–445PubMedCrossRef Stepulak A, Luksch H, Gebhardt C et al (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435–445PubMedCrossRef
30.
Zurück zum Zitat Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132:565–573 Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132:565–573
31.
Zurück zum Zitat Yip D, Le MN, Chan JL et al (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15:3896–3902PubMedCrossRef Yip D, Le MN, Chan JL et al (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15:3896–3902PubMedCrossRef
32.
Zurück zum Zitat Cavalheiro EA, Olney JW (2001) Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 98:5947–5948PubMedCrossRef Cavalheiro EA, Olney JW (2001) Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 98:5947–5948PubMedCrossRef
33.
Zurück zum Zitat Yasui K, Oketa Y, Higashida K, Fukazawa H, Ono S (2011) Increased progranulin in the skin of amyotrophic lateral sclerosis: an immunohistochemical study. J Neurol Sci 309:110–114PubMedCrossRef Yasui K, Oketa Y, Higashida K, Fukazawa H, Ono S (2011) Increased progranulin in the skin of amyotrophic lateral sclerosis: an immunohistochemical study. J Neurol Sci 309:110–114PubMedCrossRef
34.
Zurück zum Zitat Watanabe T, Okeda Y, Yamano T, Ono S (2010) An immunohistochemical study of ubiquitin in the skin of sporadic amyotrophic lateral sclerosis. J Neurol Sci 298:52–56PubMedCrossRef Watanabe T, Okeda Y, Yamano T, Ono S (2010) An immunohistochemical study of ubiquitin in the skin of sporadic amyotrophic lateral sclerosis. J Neurol Sci 298:52–56PubMedCrossRef
35.
Zurück zum Zitat Suzuki M, Mikami H, Watanabe T et al (2010) Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 122:367–372PubMedCrossRef Suzuki M, Mikami H, Watanabe T et al (2010) Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 122:367–372PubMedCrossRef
36.
Zurück zum Zitat Nomura M, Oketa Y, Yasui K, Ishikawa H, Ono S (2012) Expression of hepatocyte growth factor in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 125:389–397 Nomura M, Oketa Y, Yasui K, Ishikawa H, Ono S (2012) Expression of hepatocyte growth factor in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 125:389–397
37.
Zurück zum Zitat Bogenrieder T, Herlyn M (2010) The molecular pathology of cutaneous melanoma. Cancer Biomark 9:267–286PubMed Bogenrieder T, Herlyn M (2010) The molecular pathology of cutaneous melanoma. Cancer Biomark 9:267–286PubMed
38.
Zurück zum Zitat Park SY, Lee SA, Han IH et al (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17:81–87PubMed Park SY, Lee SA, Han IH et al (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17:81–87PubMed
39.
Zurück zum Zitat Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124:1398–1403PubMedCrossRef Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124:1398–1403PubMedCrossRef
40.
Zurück zum Zitat Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416–2429PubMedCrossRef Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416–2429PubMedCrossRef
41.
Zurück zum Zitat Sakowski SA, Schuyler AD, Feldman EL (2009) Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10:63–73PubMedCrossRef Sakowski SA, Schuyler AD, Feldman EL (2009) Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10:63–73PubMedCrossRef
42.
Zurück zum Zitat Sorenson EJ, Windbank AJ, Mandrekar JN et al (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71:1770–1775PubMedCrossRef Sorenson EJ, Windbank AJ, Mandrekar JN et al (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71:1770–1775PubMedCrossRef
43.
Zurück zum Zitat Bilak MM, Kuncl RW (2001) Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. NeuroReport 12:2531–2535PubMedCrossRef Bilak MM, Kuncl RW (2001) Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. NeuroReport 12:2531–2535PubMedCrossRef
44.
Zurück zum Zitat Marin B, Couratier P, Preux PM, Logroscino G (2011) Can mortality data be used to estimate amyotrophic lateral sclerosis incidence? Neuroepidemiology 36:29–38PubMedCrossRef Marin B, Couratier P, Preux PM, Logroscino G (2011) Can mortality data be used to estimate amyotrophic lateral sclerosis incidence? Neuroepidemiology 36:29–38PubMedCrossRef
Metadaten
Titel
The association between cancer and amyotrophic lateral sclerosis
verfasst von
D. Michal Freedman
Rochelle E. Curtis
Sarah E. Daugherty
James J. Goedert
Ralph W. Kuncl
Margaret A. Tucker
Publikationsdatum
01.01.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 1/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0089-5

Weitere Artikel der Ausgabe 1/2013

Cancer Causes & Control 1/2013 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.